A model shows that replacing the current 23-valent pneumococcal polysaccharide vaccine (PPSV23) with the 13-valent pneumococcal conjugate vaccine (PCV13) might prevent more pneumococcal disease, while remaining economically reasonable.
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.